MétaCan
Menu
Back to cohort
Record W1907039258 · doi:10.1111/apt.13408

Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

2015· article· en· W1907039258 on OpenAlexaff
Vipul Jairath, Reena Khanna, Guangyong Zou, Larry Stitt, Mahmoud Mosli, Margaret K. Vandervoort, Geert D’Haens, William J. Sandborn, Brian G. Feagan, Barrett G. Levesque

Bibliographic record

VenueAlimentary Pharmacology & Therapeutics · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsRobarts Clinical TrialsWestern University
FundersUCB PharmaTakeda OncologyTillotts PharmaGenentechBiogenCelgeneNational Institute for Health and Care ResearchTeva Pharmaceutical IndustriesGilead SciencesWyeth PharmaceuticalsPfizerActoGeniXBristol-Myers Squibb
KeywordsMedicineUlcerative colitisMesalazinePlaceboInternal medicineInterim analysisClinical trialInflammatory bowel diseaseClinical endpointInterimEndoscopyColonoscopyGastroenterologyDiseaseSurgeryPathologyAlternative medicineColorectal cancer

Abstract

fetched live from OpenAlex

BACKGROUND: Patient-reported outcomes (PROs) have an increasingly important role in the evaluation of new therapies for inflammatory bowel disease. The US Food and Drug Administration has issued formal guidance to describe the role of PRO instruments in evaluation of claims for product labelling. However, no validated PRO exists for ulcerative colitis. AIM: To investigate whether the PROs from the Mayo Clinic Score (MCS) for UC can be modified, to develop an interim PRO for use in clinical trials, alone or in combination with endoscopy. METHODS: Data from an induction trial of a mesalazine (mesalamine) formulation were used to compare effect sizes between mesalazine and placebo for PRO items (stool frequency and rectal bleeding) alone and in combination with endoscopy. The operating properties of the PRO were validated using data from a phase 2 trial of MLN02, a humanised antibody to the α4β7 integrin in patients with UC. RESULTS: A two-item PRO (PRO2) consisting of rectal bleeding = 0 and stool frequency ≤1 or ≤2, combined with an endoscopy subscore ≤1 yielded statistically significant differences between active drug and placebo. This combination yielded the most similar effect sizes and placebo rates for remission, compared to the primary trials. Use of PRO items alone yielded high placebo remission rates in both data sets, although rates were lower when the items were combined and remission defined as PRO2 = 0. CONCLUSION: Patient-reported outcomes items derived from the Mayo Clinic Score combined with endoscopy as a co-primary endpoint may be an appropriate interim outcome measure for ulcerative colitis trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.463
metaresearch head score (Gemma)0.524
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: Methods
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.537
Threshold uncertainty score0.662

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.4630.524
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0070.013
Bibliometrics0.0060.006
Science and technology studies0.0010.003
Scholarly communication0.0050.004
Open science0.0030.004
Research integrity0.0030.006
Insufficient payload (model declined to judge)0.0070.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.251
GPT teacher head0.485
Teacher spread0.235 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designObservational
DomainMethods
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations173
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueAlimentary Pharmacology & TherapeuticsSame topicInflammatory Bowel DiseaseFrench-language works237,207